top of page

Chronic Inflammation

to Treat Neurodegeneration & Inflammatory Diseases by Targeting the NLRP3 Inflammasome

Halia’s Dedication to
Inflammation Drug Discovery

At Halia Therapeutics, we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.

Founded in 2017, our incredible team of scientists has worked tirelessly to bring Halia Therapeutics to the forefront in the field of inflammation drug discovery. We will continue to work relentlessly to translate our work into new medicines for patients.


Advancing Novel NLRP3 Inflammasome Therapeutics


We have leveraged our core capabilities in targeting the underlying causes of inflammation and neurological diseases to build a discovery engine that has produced a pipeline of novel therapies we are advancing into the clinic.


We are growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.


We use an innovative approach to drug discovery by translating advances in the understanding of the importance of inflammation in human pathologies such as cancer and neurodegenerative diseases.


Our Pipeline Targets Immune Cell Signaling


We Are Experienced in Drug Discovery for Oncology and Neurodegeneration

Our scientists have made fundamental discoveries in the fields of oncology, Alzheimer's disease, and other neurodegenerative disorders, and we leverage these experiences to identify novel targets to treat these diseases.

bottom of page